Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Bicara Therapeutics Price Performance
Shares of NASDAQ BCAX traded down $1.34 during trading hours on Wednesday, reaching $25.73. The stock had a trading volume of 299,459 shares, compared to its average volume of 502,486. Bicara Therapeutics Inc. has a fifty-two week low of $21.05 and a fifty-two week high of $27.94.
Bicara Therapeutics Company Profile
Further Reading
- Five stocks we like better than Bicara Therapeutics
- Conference Calls and Individual Investors
- This Is the Top Large-Cap Stock Insiders Are Buying
- What is a support level?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- ESG Stocks, What Investors Should Know
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.